IP Library Patent Application 15091703
Patent Application
App. No. 15/091,703

Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/091,703
Abstract

In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R 1 , R 2 , and R 3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R 4 and R 5 is independently hydrogen, alkyl, or alkoxy; and each of R 6 and R 7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A 1 , A 3 , and A 4 is independently hydrogen or alkyl; and A 2 is independently hydrogen or hydroxy; and wherein each of B 1 , B 2 , and B 3 is independently hydrogen, hydroxy, or alkoxy; and each of B 4 and B 5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.

Claims (9)

1 . A method of treating an inflammatory skin disorder and the symptoms associated therewith, comprising topically administering to the skin of a patient in need of such treatment or prevention a composition comprising:

a therapeutically effective amount of at least one compound selected from the group consisting of brimonidine, xylometazoline, epinephrine, norepinephrine, phenylephrine, and methoxamine, and a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier;

wherein the inflammatory skin disorder is not rosacea.

2 - 4 . (canceled)

5 . The method according to claim 1 , wherein the at least one compound is administered in an amount sufficient to decrease blood flow through the small arteries or arterioles of the skin of the patient.

6 . The method according to claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions.

7 . The method according to claim 1 , wherein the composition acts locally in the skin of the patient.

8 - 28 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: GALDERMA LABORATORIES, L.P.
To: NESTLE SKIN HEALTH S.A.
Reel/Frame 039363/0320 →